Comment by HedonicEscal8r

mRNA vaccines are being studied for pancreatic cancer. To quote a post I wrote in April:

> First, the personalized mRNA vaccine autogene cevumeran, developed by BioNTech and Genentech, just reported 6-year follow-up results from their Phase 1 clinical trial. 16 patients were treated, 8 were responders (showed signs of immune reaction to vaccine), 8 were non-responders.

> 7/8 responders (87.5%) survived 6 years after surgery, 2/8 nonresponders survived (25%).

> AACR meeting notes https://www.aacr.org/blog/2026/04/20/live-updates-from-the-a...

> The most important result in this small trial is that vaccine response is strongly correlated with better outcomes. But for context, the trial was restricted to patients with operable pancreatic cancer. Patients diagnosed with stage 1 or 2 pancreatic cancer have a 5-year survival rate of 12%. Patients who get their pancreatic cancer surgically removed have a 5-year post-surgery survival rate of 20%. This makes the overall 6-year post-surgery survival rate of 56% among the 16 trial patients pretty impressive. Keep in mind that the trial patients may have been healthier than average for other reasons, and small n is small n, so we shouldn't be too hasty until we see Phase 2 and 3 data.

> Source on survival rates https://www.pancreaticcancer.org.uk/information/just-diagnos...

Still early, unfortunately, so it will be a while before we see more updates.